Australia's Cleo Diagnostics hits near 2-week high on cancer program progress

CLEO Diagnostics

09/10/2023 05:44

** Shares of Australian based medical diagnostics company
Cleo Diagnostics  COV.AX  rise as much as 2.8% to A$0.185,
highest level since Sept. 26
    ** Co says selection of biomarkers panel for Co's ovarian
cancer test-kit been finalised
    ** Antibody development has advanced increasing confidence
for commercial assay development & upscaling for commercial
manufacturing - COV
    ** Adds in final stages evaluating four commercial antibody
manufacturing partners 
    ** Nearly 1.0 mln shares change hands as of 0433 GMT, vs the
30-day average volume of 87,618
    ** As of last close, stock down 14.3% since listing on Aug.
22

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))